These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15466762)

  • 1. Summaries for patients. The cost-effectiveness of screening for Chlamydia in women 15 to 29 years of age.
    Ann Intern Med; 2004 Oct; 141(7):I29. PubMed ID: 15466762
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.
    Hu D; Hook EW; Goldie SJ
    Ann Intern Med; 2004 Oct; 141(7):501-13. PubMed ID: 15466767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of screening for genital Chlamydia trachomatis infection in Australia.
    Walleser S; Salkeld G; Donovan B
    Sex Health; 2006 Dec; 3(4):225-34. PubMed ID: 17112432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women.
    Rours GI; Smith-Norowitz TA; Ditkowsky J; Hammerschlag MR; Verkooyen RP; de Groot R; Verbrugh HA; Postma MJ
    Pathog Glob Health; 2016; 110(7-8):292-302. PubMed ID: 27958189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches.
    Postma MJ; Welte R; van den Hoek JA; Morré SA
    Sex Transm Infect; 2002 Feb; 78(1):73-4. PubMed ID: 11872873
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis.
    Postma MJ; Welte R; van den Hoek JA; van Doornum GJ; Jager HC; Coutinho RA
    Value Health; 2001; 4(3):266-75. PubMed ID: 11705188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland.
    Gillespie P; O'Neill C; Adams E; Turner K; O'Donovan D; Brugha R; Vaughan D; O'Connell E; Cormican M; Balfe M; Coleman C; Fitzgerald M; Fleming C
    Sex Transm Infect; 2012 Apr; 88(3):222-8. PubMed ID: 22213681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility of repeated screening for Chlamydia trachomatis.
    de Vries R; van Bergen JE; de Jong-van den Berg LT; Postma MJ;
    Value Health; 2008; 11(2):272-4. PubMed ID: 18380639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data.
    de Vries R; van Bergen JE; de Jong-van den Berg LT; Postma MJ;
    Value Health; 2006; 9(1):1-11. PubMed ID: 16441519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Ruitenberg EN
    Ned Tijdschr Geneeskd; 1999 May; 143(19):1012. PubMed ID: 10368724
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infection in women.
    Gupta M; Hernon M; Gokhale R; Ghosh AK
    Sex Transm Infect; 2002 Feb; 78(1):76. PubMed ID: 11872877
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies.
    Howell MR; Quinn TC; Gaydos CA
    Ann Intern Med; 1998 Feb; 128(4):277-84. PubMed ID: 9471930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and cost-benefits of chlamydia screening in young women.
    Mangione-Smith R; O'Leary J; McGlynn EA
    Sex Transm Dis; 1999 Jul; 26(6):309-16. PubMed ID: 10417017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing.
    Morré SA; Welte R; Postma MJ
    Sex Transm Infect; 2002 Feb; 78(1):74-5. PubMed ID: 11872874
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of widespread screening for Chlamydia trachomatis.
    Postma MJ; Welte R; Morré SA
    Expert Opin Pharmacother; 2002 Oct; 3(10):1443-50. PubMed ID: 12387690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Postma MJ; Welte R; van den Hoek JA; van Doornum GJ; Coutinho RA; Jager JC
    Ned Tijdschr Geneeskd; 1999 Mar; 143(13):677-81. PubMed ID: 10321301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada.
    Tuite AR; Jayaraman GC; Allen VG; Fisman DN
    Sex Transm Dis; 2012 Apr; 39(4):260-7. PubMed ID: 22421691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment].
    Postma MJ; Welte R; van den Hoek JA; Jager JC; van Doornum GJ; Coutinho RA
    Ned Tijdschr Geneeskd; 1999 Nov; 143(47):2383-5. PubMed ID: 10590778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The silent epidemic of Chlamydia: what are we missing here?
    Sanfilippo JS
    J Pediatr Adolesc Gynecol; 2008 Oct; 21(5):231-2. PubMed ID: 18794016
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies.
    Hu D; Hook EW; Goldie SJ
    Sex Transm Dis; 2006 Jul; 33(7):428-36. PubMed ID: 16572038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.